Bitcoin’s recent drop below $60,000, combined with massive exchange inflows and a deteriorating Sharpe ratio, reflects heightened market volatility and extreme Bitcoin’s recent drop below $60,000, combined with massive exchange inflows and a deteriorating Sharpe ratio, reflects heightened market volatility and extreme

Bitcoin Faces Sharp Correction As Exchange Inflows And Short-Term Holder Selling Intensify Market Volatility

2026/02/09 20:19
4 min read
Bitcoin Faces Sharp Correction as Exchange Inflows and Short-Term Holder Selling Intensify Market Volatility

Cryptocurrency market analyst Darkfost of blockchain research firm CryptoQuant released a comprehensive market briefing indicating that recent trading sessions have been especially challenging for Bitcoin and the wider digital asset market.

In a post on the social media platform X, he outlined that on February 6th, Bitcoin dropped below the $60,000 mark, a price level that had not been seen since October 2024. The decline occurred alongside a pronounced market-wide correction, with prices retreating by more than 50% from the most recent all-time high. The sudden return to lower valuation levels revived concerns among investors and contributed to a fast deterioration in overall market sentiment.

The pace of the sell-off fostered a clearly fear-driven environment. A large number of market participants moved their Bitcoin holdings onto centralized exchanges, intensifying an already heavy wave of forced liquidations. Short-term holders were identified as the earliest and most reactive group during this phase, responding quickly to the sharp price movements.

Data from Binance, which accounts for a substantial portion of global trading activity, showed that Bitcoin inflows attributed to short-term holders, measured on a seven-day cumulative basis, exceeded 100,000 BTC on February 6th alone. This figure surpassed the volumes observed during the market correction in April 2025. Such elevated inflow levels are commonly interpreted as a sign of capitulation and underline the large influence this investor segment had on the selling pressure during the downturn.

The analyst continued, highlighting that between February 4th and February 6th, approximately 241,000 BTC were transferred to multiple cryptocurrency exchanges. When deposit flows of this scale converge on trading venues, they are generally viewed as reflecting a prevailing intention to sell rather than to hold. The surge in exchange deposits further amplified volatility, which was already elevated across digital asset markets.

A comparable trend was observed on Coinbase Advanced, a trading platform predominantly used by institutional investors, active traders, and professional trading desks. On February 6th, Bitcoin inflows to the platform reached an estimated 27,000 BTC, representing a notable spike in transactional activity. This indicates that the sense of uncertainty extended beyond retail traders and also affected more experienced and professionally managed market participants.

The episode demonstrates how a fast-moving correction can intensify panic-driven behavior and lead to widespread capitulation across different segments of the market. As a result of these liquidation and selling dynamics, Bitcoin has entered an extreme oversold condition, suggesting that the market may require a period of adjustment before absorbing the recent shock.

Bitcoin’s Sharpe Ratio Signals Extreme Risk Levels Amid Late-Stage Bear Market Conditions

In a separate report, the analyst highlighted that the Sharpe ratio for Bitcoin has recently entered a zone historically associated with the later stages of bear markets. This does not indicate that the downtrend has ended, but it signals that the risk-to-reward profile has become particularly extreme. Currently, the level of risk involved in holding or investing in Bitcoin remains high compared with recent returns, and the ratio continues to deteriorate, reflecting the ongoing underperformance relative to risk.

Such conditions, however, often emerge near potential market turning points. The Sharpe ratio should be interpreted as a reflective metric rather than a predictive one, showing the outcomes of recent market activity rather than causing them. The continued low performance suggests that many investors are experiencing losses or pressure, a situation that historically coincides with the emergence of long-term opportunities.

From this point, two main approaches are typically considered. One is to begin gradually accumulating Bitcoin as the ratio moves closer to historically lower-risk levels. The other is to wait until the Sharpe ratio shows clear improvement before increasing exposure.

He further noted that it is important to maintain realistic expectations regarding timing, as this phase could extend for several months and the price of Bitcoin may continue to correct before a sustained reversal occurs. While the signal is structurally constructive, it requires time to fully materialize, and immediate action is not necessarily warranted.

At the time of writing, Bitcoin is trading at $68,857, reflecting a decline of more than 2.26 percent over the previous 24 hours. During this period, the lowest recorded price was $68,446, while the session high reached $71,878. The total capitalization of the global cryptocurrency market stands at $2.34 trillion, representing a 2.26% decrease over the last day, according to data from CoinMarketCap.

The post Bitcoin Faces Sharp Correction As Exchange Inflows And Short-Term Holder Selling Intensify Market Volatility appeared first on Metaverse Post.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26